We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Is Serious About Postmarket Safety and Monitoring
FDA Is Serious About Postmarket Safety and Monitoring
May 6, 2010
Nowhere is such a systemic, cross-functional monitoring and evaluation program more critical than in the postapproval stage, when finished products are
distributed and sold to healthcare providers and patients. The Food and Drug Administration Amendments Act (FDAAA) has as its strongest provision Title
IX – Enhanced Authorities Regarding Postmarket Safety of Drugs.